Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Company Overview

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Key Stats

• Today's Range: $14.68 to $15.34
• 50-Day Range: $10.90 to $15.50
• 52-Week Range: $5.49 to $33.00
• Volume: 44,004 shs
• Average Volume: 243,408 shs
• Market Capitalization: $554.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.38
• Consensus Rating: Buy

Oruka Therapeutics Stock Analysis - MarketRank™

Oruka Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 565th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Oruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oruka Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oruka Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oruka Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oruka Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ORKA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oruka Therapeutics does not currently pay a dividend.

Dividend Growth

Oruka Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ORKA.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.92

News Sentiment

Oruka Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ORKA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.69% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORKA Stock Analysis - Frequently Asked Questions

How have ORKA shares performed this year?

Oruka Therapeutics' stock was trading at $19.39 at the beginning of 2025. Since then, ORKA shares have decreased by 22.3% and is now trading at $15.06.

How were Oruka Therapeutics' earnings last quarter?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings data on Monday, August, 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02.

Who are Oruka Therapeutics' major shareholders?

Oruka Therapeutics' top institutional shareholders include Braidwell LP (4.07%), Franklin Resources Inc. (2.71%), Geode Capital Management LLC (1.89%) and Affinity Asset Advisors LLC (1.61%).
View institutional ownership trends.

How do I buy shares of Oruka Therapeutics?

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oruka Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORKA
• Previous Symbol: NASDAQ:ORKA
• CIK: 907654
• Web: www.arcabio.com
• Phone: 720-940-2100
• Fax: 720-208-9261
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oruka Therapeutics: $40.38
• High Price Target: $49.00
• Low Price Target: $20.00
• Potential Upside/Downside: +164.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.72 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.26%
• Return on Assets: -24.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.42
• Quick Ratio: 27.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.10 per share
• Price / Book: 1.68

Miscellaneous

• Outstanding Shares: 37,450,000
• Free Float: 28,204,000
• Market Cap: $571.86 million
• Optionable: N/A
• Beta: -0.35